<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817087</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00014213</org_study_id>
    <nct_id>NCT02817087</nct_id>
  </id_info>
  <brief_title>Multifocal Brain Magnetic Stimulation in Chronic Ischemic Stroke</brief_title>
  <official_title>An Innovative Approach to Restoration of Function in Chronic Ischemic Stroke Using a New Wearable Multifocal Brain Stimulator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Chiu, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Methodist Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seraya Medical Systems, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Methodist Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcranial magnetic stimulation for post-stroke upper-body motor deficits.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study uses transcranial magnetic stimulation (magnetic pulses delivered through a&#xD;
      specially designed cap worn on the head aimed at specific motor areas of the brain (brain&#xD;
      areas responsible for the body's physical movements) to test whether upper-body motor&#xD;
      function can be improved.&#xD;
&#xD;
      This is a double-blind study where half of participants will receive active transcranial&#xD;
      stimulation and the other half of the participants will receive no transcranial magnetic&#xD;
      stimulation; all participants will wear the cap. Participants and some members of the&#xD;
      research team will not know who received active magnetic brain stimulation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 27, 2016</start_date>
  <completion_date type="Actual">March 13, 2019</completion_date>
  <primary_completion_date type="Actual">March 13, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Active repetitive transcranial magnetic stimulation administered through cap worn by patient under healthcare provider.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind, only the care provider is aware of active treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Brain Activation</measure>
    <time_frame>One business day before treatment begins, one business day after treatment ends, up to 5 weeks</time_frame>
    <description>Change in number of active voxels in the cortical areas surrounding the lesion on functional MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fugl-Meyer Motor Arm Score</measure>
    <time_frame>One business day before treatment begins, one business day after treatment ends up to 5 weeks</time_frame>
    <description>Change in arm motor function Total score range is 0-66 with the higher number representing a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARAT (Action Research Arm Test)</measure>
    <time_frame>One business day before treatment begins, one business day after treatment ends up to 5 weeks</time_frame>
    <description>Change in arm and hand motor function Total score range is 0-57 with the higher number representing a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand Dynamometer</measure>
    <time_frame>One business day before treatment begins, one business day after treatment ends up to 5 weeks</time_frame>
    <description>Change in grip strength The higher the number represents better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pinch Dynamometer Score</measure>
    <time_frame>One business day before treatment begins, one business day after treatment ends up to 5 weeks</time_frame>
    <description>Change in pinch strength. The higher the number, the better the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TUG (Timed Up and Go Test)</measure>
    <time_frame>One business day before treatment begins, one business day after treatment ends up to 5 weeks</time_frame>
    <description>Change in gait velocity on Timed Up and Go Test. The lower the time recorded, the better the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>One business day before treatment begins, one business day after treatment ends up to 5 weeks</time_frame>
    <description>Change in National Institutes of Health Stroke Scale (NIHSS) Total score range is 0-42 with the lower number representing a better outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>repetitive Transcranial Magnetic Stimulation -On</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap delivering magnetic stimulation to part of the brain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>repetitive Transcranial Magnetic Stimulation -Off</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap that does NOT delivery any magnetic stimulation to the brain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>repetitive Transcranial Magnetic Stimulation -On</intervention_name>
    <description>Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain</description>
    <arm_group_label>repetitive Transcranial Magnetic Stimulation -On</arm_group_label>
    <other_name>transcranial magnetic stimulation (TMS)</other_name>
    <other_name>Transcranial Rotating Permanent Magnet Stimulation (TRPMS)</other_name>
    <other_name>repetitive Transcranial Magnetic Stimulation (rTMS)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>repetitive Transcranial Magnetic Stimulation -Off</intervention_name>
    <description>Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.</description>
    <arm_group_label>repetitive Transcranial Magnetic Stimulation -Off</arm_group_label>
    <other_name>sham treatment</other_name>
    <other_name>Control Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18-80 years;&#xD;
&#xD;
          -  Clinical diagnosis of chronic ischemic stroke recovering for more than 3 months with&#xD;
             unilateral motor deficits of arm and leg, or arm alone; --&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of seizure;&#xD;
&#xD;
          -  Epileptogenic activity (indicative of increased risk of seizures) on EEG;&#xD;
&#xD;
          -  Any active unstable medical condition;&#xD;
&#xD;
          -  Pregnancy;&#xD;
&#xD;
          -  Schizophrenia, bipolar disorder, alcoholism, or substance abuse;&#xD;
&#xD;
          -  Medications which in the investigator's clinical judgment significantly lower the&#xD;
             seizure threshold;&#xD;
&#xD;
          -  Presence of metal or electronic implants in the head (or any in the body that preclude&#xD;
             MRI) , including pacemakers, defibrillators, aneurysm clips, neuro-stimulators,&#xD;
             cochlear implants, metal in the eyes, etc.;&#xD;
&#xD;
          -  Any changes in medications prescribed for the treatment of stroke impairment within&#xD;
             six weeks prior to inclusion in the study or at any time during the study.&#xD;
&#xD;
          -  Botulinum toxin use within two months prior to the screening visit or any planned use&#xD;
             of botulinum toxin during the study&#xD;
&#xD;
          -  Changes in NIHSS and motor assessment scores between Visit 1 and Visit 2 indicating&#xD;
             that the patient's impairment is not stable. The following cutoffs, based on research&#xD;
             establishing Clinically Important Differences, will be used for this determination:&#xD;
&#xD;
          -  National Institutes of Health Stroke Scale: A change in total score of more than 2&#xD;
             points in either direction, or a change in the motor extremity score of more than 1&#xD;
             point in either direction.&#xD;
&#xD;
          -  Fugl-Meyer Assessment of Sensorimotor Impairment: A change of more than 5 points in&#xD;
             either direction on the upper-extremity motor score for the affected arm.&#xD;
&#xD;
          -  Action Research Arm Test: A change of more than 5 points in either direction on the&#xD;
             ARAT score for the affected arm.&#xD;
&#xD;
          -  Any condition that precludes a high quality brain MRI scan.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Chiu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Methodist Hospital Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rehme AK, Grefkes C. Cerebral network disorders after stroke: evidence from imaging-based connectivity analyses of active and resting brain states in humans. J Physiol. 2013 Jan 1;591(1):17-31. doi: 10.1113/jphysiol.2012.243469. Epub 2012 Oct 22. Review.</citation>
    <PMID>23090951</PMID>
  </reference>
  <reference>
    <citation>Li W, Li Y, Zhu W, Chen X. Changes in brain functional network connectivity after stroke. Neural Regen Res. 2014 Jan 1;9(1):51-60. doi: 10.4103/1673-5374.125330.</citation>
    <PMID>25206743</PMID>
  </reference>
  <reference>
    <citation>Varsou O, Macleod MJ, Schwarzbauer C. Functional connectivity magnetic resonance imaging in stroke: an evidence-based clinical review. Int J Stroke. 2014 Feb;9(2):191-8. doi: 10.1111/ijs.12033. Epub 2013 Mar 19. Review.</citation>
    <PMID>23506092</PMID>
  </reference>
  <reference>
    <citation>Ameli M, Grefkes C, Kemper F, Riegg FP, Rehme AK, Karbe H, Fink GR, Nowak DA. Differential effects of high-frequency repetitive transcranial magnetic stimulation over ipsilesional primary motor cortex in cortical and subcortical middle cerebral artery stroke. Ann Neurol. 2009 Sep;66(3):298-309. doi: 10.1002/ana.21725.</citation>
    <PMID>19798637</PMID>
  </reference>
  <reference>
    <citation>Chang WH, Kim YH, Bang OY, Kim ST, Park YH, Lee PK. Long-term effects of rTMS on motor recovery in patients after subacute stroke. J Rehabil Med. 2010 Sep;42(8):758-64. doi: 10.2340/16501977-0590.</citation>
    <PMID>20809058</PMID>
  </reference>
  <reference>
    <citation>Kim YH, You SH, Ko MH, Park JW, Lee KH, Jang SH, Yoo WK, Hallett M. Repetitive transcranial magnetic stimulation-induced corticomotor excitability and associated motor skill acquisition in chronic stroke. Stroke. 2006 Jun;37(6):1471-6. Epub 2006 May 4. Erratum in: Stroke. 2006 Nov;37(11):2861.</citation>
    <PMID>16675743</PMID>
  </reference>
  <reference>
    <citation>Khedr EM, Etraby AE, Hemeda M, Nasef AM, Razek AA. Long-term effect of repetitive transcranial magnetic stimulation on motor function recovery after acute ischemic stroke. Acta Neurol Scand. 2010 Jan;121(1):30-7. doi: 10.1111/j.1600-0404.2009.01195.x. Epub 2009 Aug 11.</citation>
    <PMID>19678808</PMID>
  </reference>
  <reference>
    <citation>Fitzgerald PB, Fountain S, Daskalakis ZJ. A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition. Clin Neurophysiol. 2006 Dec;117(12):2584-96. Epub 2006 Aug 4. Review.</citation>
    <PMID>16890483</PMID>
  </reference>
  <reference>
    <citation>Fregni F, Boggio PS, Valle AC, Rocha RR, Duarte J, Ferreira MJ, Wagner T, Fecteau S, Rigonatti SP, Riberto M, Freedman SD, Pascual-Leone A. A sham-controlled trial of a 5-day course of repetitive transcranial magnetic stimulation of the unaffected hemisphere in stroke patients. Stroke. 2006 Aug;37(8):2115-22. Epub 2006 Jun 29.</citation>
    <PMID>16809569</PMID>
  </reference>
  <reference>
    <citation>MÃ¡lly J, Dinya E. Recovery of motor disability and spasticity in post-stroke after repetitive transcranial magnetic stimulation (rTMS). Brain Res Bull. 2008 Jul 1;76(4):388-95. doi: 10.1016/j.brainresbull.2007.11.019. Epub 2007 Dec 26.</citation>
    <PMID>18502315</PMID>
  </reference>
  <reference>
    <citation>Boggio PS, Alonso-Alonso M, Mansur CG, Rigonatti SP, Schlaug G, Pascual-Leone A, Fregni F. Hand function improvement with low-frequency repetitive transcranial magnetic stimulation of the unaffected hemisphere in a severe case of stroke. Am J Phys Med Rehabil. 2006 Nov;85(11):927-30.</citation>
    <PMID>17079967</PMID>
  </reference>
  <reference>
    <citation>Grefkes C, Nowak DA, Wang LE, Dafotakis M, Eickhoff SB, Fink GR. Modulating cortical connectivity in stroke patients by rTMS assessed with fMRI and dynamic causal modeling. Neuroimage. 2010 Mar;50(1):233-42. doi: 10.1016/j.neuroimage.2009.12.029. Epub 2009 Dec 18.</citation>
    <PMID>20005962</PMID>
  </reference>
  <reference>
    <citation>Helekar, S.A., et al., Electromyographic motor-evoked potentials elicited by transcranial magnetic stimulation with rapidly moving permanent magnets mounted on a multisite stimulator cap, in 2013 Neuroscience Meeting Planner. 2013, Society for Neuroscience: San Diego, CA.</citation>
  </reference>
  <reference>
    <citation>Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Hum Brain Mapp. 1999;7(4):254-66.</citation>
    <PMID>10408769</PMID>
  </reference>
  <reference>
    <citation>Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002 Jan;15(1):273-89.</citation>
    <PMID>11771995</PMID>
  </reference>
  <reference>
    <citation>Bressler SL, Seth AK. Wiener-Granger causality: a well established methodology. Neuroimage. 2011 Sep 15;58(2):323-9. doi: 10.1016/j.neuroimage.2010.02.059. Epub 2010 Mar 2.</citation>
    <PMID>20202481</PMID>
  </reference>
  <reference>
    <citation>Matias FS, Gollo LL, Carelli PV, Bressler SL, Copelli M, Mirasso CR. Modeling positive Granger causality and negative phase lag between cortical areas. Neuroimage. 2014 Oct 1;99:411-8. doi: 10.1016/j.neuroimage.2014.05.063. Epub 2014 Jun 2.</citation>
    <PMID>24893321</PMID>
  </reference>
  <reference>
    <citation>Chen Y, Bressler SL, Ding M. Frequency decomposition of conditional Granger causality and application to multivariate neural field potential data. J Neurosci Methods. 2006 Jan 30;150(2):228-37. Epub 2005 Aug 15.</citation>
    <PMID>16099512</PMID>
  </reference>
  <reference>
    <citation>Blair RC, Karniski W. An alternative method for significance testing of waveform difference potentials. Psychophysiology. 1993 Sep;30(5):518-24.</citation>
    <PMID>8416078</PMID>
  </reference>
  <reference>
    <citation>Chiavarini M, Morini G, Barocelli E, Bordi F, Plazzi PV, Vitali T, Impicciatore M. Influence of urea-equivalent groups in position 5 of 2-amino, 2-(1-aminoethylidenamino) and 2-guanidino thiazole derivatives on H2-receptor antagonist activity in gastric fistula cat. Agents Actions. 1989 Apr;27(1-2):192-4.</citation>
    <PMID>2568739</PMID>
  </reference>
  <reference>
    <citation>Carlowe J. Investigation into home care of elderly people shows cases of &quot;serious neglect&quot;. BMJ. 2011 Jun 21;342:d3904. doi: 10.1136/bmj.d3904.</citation>
    <PMID>21693536</PMID>
  </reference>
  <reference>
    <citation>S. A. Helekar and H. U. Voss,</citation>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <results_first_submitted>March 17, 2020</results_first_submitted>
  <results_first_submitted_qc>September 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 5, 2020</results_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Methodist Hospital Research Institute</investigator_affiliation>
    <investigator_full_name>David Chiu, MD</investigator_full_name>
    <investigator_title>Principal Investigator/Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>chronic ischemic stroke</keyword>
  <keyword>cerebrovascular accident (CVA)</keyword>
  <keyword>ischaemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02817087/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02817087/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>38 patients were screened 7 were screen fails. 2 withdrawn. 14 treated-Active, 15 treated-placebo.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Repetitive Transcranial Magnetic Stimulation -On</title>
          <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap delivering magnetic stimulation to part of the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -On: Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain</description>
        </group>
        <group group_id="P2">
          <title>Repetitive Transcranial Magnetic Stimulation -Off</title>
          <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap that does NOT delivery any magnetic stimulation to the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -Off: Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14">1 pt was withdrawn early d/t concurrent disease. One pt. withdrew ICF d/t transportation concerns</participants>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>1 pt was withdrawn early d/t concurrent disease. One pt. withdrew ICF d/t transportation concerns</population>
      <group_list>
        <group group_id="B1">
          <title>Repetitive Transcranial Magnetic Stimulation -On</title>
          <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap delivering magnetic stimulation to part of the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -On: Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain</description>
        </group>
        <group group_id="B2">
          <title>Repetitive Transcranial Magnetic Stimulation -Off</title>
          <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap that does NOT delivery any magnetic stimulation to the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -Off: Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>1 pt was withdrawn early d/t concurrent disease. One pt. withdrew ICF d/t transportation concerns</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>1 pt was withdrawn early d/t concurrent disease. One pt. withdrew ICF d/t transportation concerns</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.4" lower_limit="47" upper_limit="78"/>
                    <measurement group_id="B2" value="66.3" lower_limit="45" upper_limit="80"/>
                    <measurement group_id="B3" value="65.8" lower_limit="45" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>1 pt was withdrawn early d/t concurrent disease. One pt. withdrew ICF d/t transportation concerns</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>pt was withdrawn early d/t concurrent disease. One pt. withdrew ICF d/t transportation concerns</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>pt was withdrawn early d/t concurrent disease. One pt. withdrew ICF d/t transportation concerns</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>1 pt was withdrawn early d/t concurrent disease. One pt. withdrew ICF d/t transportation concerns</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fugl-Meyer motor arm score</title>
          <description>Scale range is 0-66 with higher score representing a better outcome.</description>
          <population>1 pt was withdrawn early d/t concurrent disease. One pt. withdrew ICF d/t transportation concerns</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="16" upper_limit="56"/>
                    <measurement group_id="B2" value="25" lower_limit="15" upper_limit="52"/>
                    <measurement group_id="B3" value="37.0" lower_limit="15.75" upper_limit="54.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>National Institutes of Health Stroke Scale (NIHSS)</title>
          <description>Total score is 0-42, with the lower score representing a better outcome</description>
          <population>1 pt was withdrawn early d/t concurrent disease. One pt. withdrew ICF d/t transportation concerns</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="B2" value="3" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="B3" value="3.0" lower_limit="1.75" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Action Research Arm Test (ARAT)</title>
          <description>Total score is 0-57 with the higher score representing a better outcome</description>
          <population>1 pt was withdrawn early d/t concurrent disease. One pt. withdrew ICF d/t transportation concerns</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" lower_limit="0" upper_limit="57"/>
                    <measurement group_id="B2" value="6" lower_limit="0" upper_limit="53"/>
                    <measurement group_id="B3" value="14.0" lower_limit="0.0" upper_limit="56.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hand Grip Strength</title>
          <population>1 pt was withdrawn early d/t concurrent disease. One pt. withdrew ICF d/t transportation concerns</population>
          <units>Pounds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.7" lower_limit="0" upper_limit="44"/>
                    <measurement group_id="B2" value="30.6" lower_limit="0" upper_limit="54.4"/>
                    <measurement group_id="B3" value="21.8" lower_limit="0.0" upper_limit="46.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pinch Strength</title>
          <population>1 pt was withdrawn early d/t concurrent disease. One pt. withdrew ICF d/t transportation concerns</population>
          <units>Pounds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="B2" value="3.83" lower_limit="1" upper_limit="9.67"/>
                    <measurement group_id="B3" value="4.7" lower_limit="0.75" upper_limit="9.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gait velocity on Timed Up and Go Test</title>
          <population>1 pt was withdrawn early d/t concurrent disease. One pt. withdrew ICF d/t transportation concerns</population>
          <units>feet per second</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.32" lower_limit="0" upper_limit="1.69"/>
                    <measurement group_id="B2" value="1.45" lower_limit="0" upper_limit="1.74"/>
                    <measurement group_id="B3" value="1.45" lower_limit="0.0" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Brain Activation</title>
        <description>Change in number of active voxels in the cortical areas surrounding the lesion on functional MRI</description>
        <time_frame>One business day before treatment begins, one business day after treatment ends, up to 5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Repetitive Transcranial Magnetic Stimulation -On</title>
            <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap delivering magnetic stimulation to part of the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -On: Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain</description>
          </group>
          <group group_id="O2">
            <title>Repetitive Transcranial Magnetic Stimulation -Off</title>
            <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap that does NOT delivery any magnetic stimulation to the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -Off: Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Brain Activation</title>
          <description>Change in number of active voxels in the cortical areas surrounding the lesion on functional MRI</description>
          <units>voxels</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5" lower_limit="-60" upper_limit="81"/>
                    <measurement group_id="O2" value="-30" lower_limit="-373.3" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fugl-Meyer Motor Arm Score</title>
        <description>Change in arm motor function Total score range is 0-66 with the higher number representing a better outcome</description>
        <time_frame>One business day before treatment begins, one business day after treatment ends up to 5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Repetitive Transcranial Magnetic Stimulation -On</title>
            <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap delivering magnetic stimulation to part of the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -On: Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain</description>
          </group>
          <group group_id="O2">
            <title>Repetitive Transcranial Magnetic Stimulation -Off</title>
            <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap that does NOT delivery any magnetic stimulation to the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -Off: Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Fugl-Meyer Motor Arm Score</title>
          <description>Change in arm motor function Total score range is 0-66 with the higher number representing a better outcome</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-1.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ARAT (Action Research Arm Test)</title>
        <description>Change in arm and hand motor function Total score range is 0-57 with the higher number representing a better outcome</description>
        <time_frame>One business day before treatment begins, one business day after treatment ends up to 5 weeks</time_frame>
        <population>Stroke patients greater than 3 months from qualifying stroke date</population>
        <group_list>
          <group group_id="O1">
            <title>Repetitive Transcranial Magnetic Stimulation -On</title>
            <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap delivering magnetic stimulation to part of the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -On: Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain</description>
          </group>
          <group group_id="O2">
            <title>Repetitive Transcranial Magnetic Stimulation -Off</title>
            <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap that does NOT delivery any magnetic stimulation to the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -Off: Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>ARAT (Action Research Arm Test)</title>
          <description>Change in arm and hand motor function Total score range is 0-57 with the higher number representing a better outcome</description>
          <population>Stroke patients greater than 3 months from qualifying stroke date</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hand Dynamometer</title>
        <description>Change in grip strength The higher the number represents better outcome</description>
        <time_frame>One business day before treatment begins, one business day after treatment ends up to 5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Repetitive Transcranial Magnetic Stimulation -On</title>
            <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap delivering magnetic stimulation to part of the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -On: Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain</description>
          </group>
          <group group_id="O2">
            <title>Repetitive Transcranial Magnetic Stimulation -Off</title>
            <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap that does NOT delivery any magnetic stimulation to the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -Off: Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Hand Dynamometer</title>
          <description>Change in grip strength The higher the number represents better outcome</description>
          <units>pounds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0" upper_limit="4.9"/>
                    <measurement group_id="O2" value="0" lower_limit="-2.2" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pinch Dynamometer Score</title>
        <description>Change in pinch strength. The higher the number, the better the outcome.</description>
        <time_frame>One business day before treatment begins, one business day after treatment ends up to 5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Repetitive Transcranial Magnetic Stimulation -On</title>
            <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap delivering magnetic stimulation to part of the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -On: Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain</description>
          </group>
          <group group_id="O2">
            <title>Repetitive Transcranial Magnetic Stimulation -Off</title>
            <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap that does NOT delivery any magnetic stimulation to the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -Off: Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Pinch Dynamometer Score</title>
          <description>Change in pinch strength. The higher the number, the better the outcome.</description>
          <units>pounds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".17" lower_limit="0" upper_limit=".67"/>
                    <measurement group_id="O2" value=".33" lower_limit="0" upper_limit=".83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TUG (Timed Up and Go Test)</title>
        <description>Change in gait velocity on Timed Up and Go Test. The lower the time recorded, the better the outcome.</description>
        <time_frame>One business day before treatment begins, one business day after treatment ends up to 5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Repetitive Transcranial Magnetic Stimulation -On</title>
            <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap delivering magnetic stimulation to part of the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -On: Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain</description>
          </group>
          <group group_id="O2">
            <title>Repetitive Transcranial Magnetic Stimulation -Off</title>
            <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap that does NOT delivery any magnetic stimulation to the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -Off: Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>TUG (Timed Up and Go Test)</title>
          <description>Change in gait velocity on Timed Up and Go Test. The lower the time recorded, the better the outcome.</description>
          <units>feet per second</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".04" lower_limit="0" upper_limit=".11"/>
                    <measurement group_id="O2" value="0" lower_limit="-.11" upper_limit=".12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>National Institutes of Health Stroke Scale (NIHSS)</title>
        <description>Change in National Institutes of Health Stroke Scale (NIHSS) Total score range is 0-42 with the lower number representing a better outcome</description>
        <time_frame>One business day before treatment begins, one business day after treatment ends up to 5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Repetitive Transcranial Magnetic Stimulation -On</title>
            <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap delivering magnetic stimulation to part of the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -On: Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain</description>
          </group>
          <group group_id="O2">
            <title>Repetitive Transcranial Magnetic Stimulation -Off</title>
            <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap that does NOT delivery any magnetic stimulation to the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -Off: Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>National Institutes of Health Stroke Scale (NIHSS)</title>
          <description>Change in National Institutes of Health Stroke Scale (NIHSS) Total score range is 0-42 with the lower number representing a better outcome</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were captured from time of first treatment to completion of the final visit at 3 months post treatment. Serious adverse events were captured from time of informed consent to completion of the final visit at 3 months post treatment.</time_frame>
      <desc>All reported events were assessed by the Principal Investigator and resulted in no withdrawals due to study treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>Repetitive Transcranial Magnetic Stimulation -On</title>
          <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap delivering magnetic stimulation to part of the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -On: Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain</description>
        </group>
        <group group_id="E2">
          <title>Repetitive Transcranial Magnetic Stimulation -Off</title>
          <description>Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap that does NOT delivery any magnetic stimulation to the brain.&#xD;
repetitive Transcranial Magnetic Stimulation -Off: Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Ischemic Stroke</sub_title>
                <description>Relationship= Unlikely</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <description>Relationship=Unlikely</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <description>3 weeks post-treatment. Relationship=Unlikely</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Relationship= Unlikely</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Renal stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Transient tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Chiu, M.D.</name_or_title>
      <organization>Houston Methodist Neurological Institute</organization>
      <phone>713-441-5801</phone>
      <email>dmccane@houstonmethodist.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

